The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19.
Aline de Almeida OliveiraDiana Praia Borges FreireAna Rodrigues de AndradeAmanda de Miranda MarquesLuciana da Silva MadeiraJosé Procópio Moreno SennaIvna Alana Freitas Brasileiro da SilveiraBeatriz de Castro FialhoPublished in: Journal of pharmaceutical innovation (2023)
Even though the emergence of new VOCs is a threat to the effectiveness of this treatment, demanding constant genomic surveillance, the use of nAbs to treat and prevent COVID-19 will probably continue to be relevant due to excellent safety profiles and the possibility of immediate immunity transfer, especially in patients showing inadequate immunological response to vaccination. Therefore, we suggest that organizations should keep investing in improvements in this technology.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- randomized controlled trial
- public health
- systematic review
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- gene expression
- dna methylation
- single cell
- patient reported outcomes
- respiratory syndrome coronavirus
- dengue virus
- replacement therapy
- genome wide